![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
-HYDROXYBUTYRATE AND ACUTE LESIONS OF THE NIGRONEOSTRIATAL PATHWAY
1 Departments of Pharmacology and Psychiatry, Yale University School of Medicine, New Haven, Connecticut
-Hydroxybutyrate (GHB) and its precursor, -butyrolactone (GBL) administered in anesthetic doses have been shown to cause a rapid increase in neostriatal dopamine (DA) levels without haveing similar effects on other brain monoamines. The time course of this effect on DA has been correlated with the behavioral effects and brain levels of the drug. This study reports that high frequency electrothermic lesions placed in the nigro-neostriatal DA pathway of the rat caused a similar increase in neostriatal DA; an 80% increase was seen within 30 minutes. Histochemical fluorescence observations indicated that the site of increase in DA fluorescence observed on the side of the brain with the lesion was similar to that observed after GBL treatment. Biochemical studies with 
methyl-p-tyrosine indicated that after both GBL administration and axotomy, the increased DA levels seem protected from release and/or metabolism. Extracellular recording experiments indicated that GHB and GBL administered parenterally inhibit the firing of the units localized to the DA-containing cells of the substantia nigra. These results suggest that the increase in DA in the neostriatum caused by both GHB and electrothermic lesioning of the DA pathway results from an inhibition of impulse flow in the nigro-neostriatal pathway.
This article has been cited by other articles:
|
|
 |
|
  M. Rodriguez, I. Morales, I. Gomez, S. Gonzalez, T. Gonzalez-Hernandez, and J. L. Gonzalez-Mora Heterogeneous Dopamine Neurochemistry in the Striatum: The Fountain-Drain Matrix J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 31 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Lew, A. Garcia-Espana, K. Y. Lee, K. D. Carr, M. Goldstein, J. W. Haycock, and E. Meller Increased Site-Specific Phosphorylation of Tyrosine Hydroxylase Accompanies Stimulation of Enzymatic Activity Induced by Cessation of Dopamine Neuronal Activity Mol. Pharmacol., February 1, 1999; 55(2): 202 - 209. [Abstract] [Full Text]
|
|
|
|
|
|
T. E. Madden and S. W. Johnson Gamma-Hydroxybutyrate is a GABAB Receptor Agonist that Increases a Potassium Conductance in Rat Ventral Tegmental Dopamine Neurons J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 261 - 265. [Abstract] [Full Text]
|
|
|
|
|
|
V. Hechler, C. Ratomponirina, and M. Maitre gamma -Hydroxybutyrate Conversion into GABA Induces Displacement of GABAB Binding that is Blocked by Valproate and Ethosuximide J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 753 - 760. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
